title: [Optimization of modern conservative therapy of micropenis in hypogonadal men].
abstract: The study was aimed to the optimization of conservative therapy of micropenis in hypogonadal men using combination of traction therapy and androgen replacment therapy (ART) with injections of prolonged testosterone undecanoate (Nebido) and to evaluatiom of the safety of ART in terms of the risk of prostate cancer against the background of combined treatment of micropenis by both methods within 12 months. The study included 16 men aged 22-62 years with micropenis and hypogonadism. 10 men were diagnosed with primary hypogonadism, 6 men were diagnosed with secondary hypogonadism without reserve gonadal function; therefore, all 16 patients were treated with testosterone undecanoate 1000 mg intramuscularly according to the scheme: the second injection 6 weeks after the first injection, then each injection once a 12 weeks, the course of 12 months. During the first 3 months of ART, hypogonadism in all men was eliminated, but only at 6 month of ART, the length of the penis in the flaccid state at maximum extension increased from 5.8±1.2 to 8.3±1.2 cm (p<0.05), and the length of the erect penis - from 6.8±1.1 to 11.8±0.9 (p<0,05). At the next stage, from the 6th to the 12th month of ART, traction therapy was simultaneously carried out. At the end of the treatment, the length of the penis in the flaccid state at maximum extension increased by 58% of the original length, and in a state of erection - by 114% (p<0.05). During the 12 months of treatment, prostate volume in all men increased from 3.4±1.2 to 16.3±1.2 (p<0.05), which corresponds to the size of the prostate in healthy men. Total blood PSA level increased from 0.72±0.03 to 1.4±0.05 ng/ml (p<0.05), but it was in the acceptable range of reference values for healthy men during whole period of ART in all patients. Start therapy with prolonged testosterone undecanoate for 6 months significantly increases the efficiency of traction therapy in men with hypogonadism and micropenis, but for maintenance of the effect, ART should be continued during all period of treatment.
authors: R Iu
authors: RIu
authors: Petrovich
authors: M M
authors: MM
authors: Sokoll'shchik
authors: I A
authors: IA
authors: Tiuzikov
authors: I V
authors: IV
authors: Konstantinova
authors: M A
authors: MA
authors: Astakhova
mesh_terms: D000328:Adult; D000728:Androgens / Q000627:therapeutic use*; D005832:Genital Diseases, Male / Q000097:blood / Q000473:pathology / Q000628:therapy*; D020249:Hormone Replacement Therapy / Q000379:methods*; D006801:Humans; D007006:Hypogonadism / Q000097:blood / Q000473:pathology / Q000628:therapy*; D007610:Kallikreins / Q000097:blood; D008297:Male; D008875:Middle Aged; D010413:Penis / Q000002:abnormalities* / Q000473:pathology; D026741:Physical Therapy Modalities; D017430:Prostate-Specific Antigen / Q000097:blood; D013739:Testosterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D000728:Androgens; D013739:Testosterone; C549870:KLK3 protein, human; D007610:Kallikreins; D017430:Prostate-Specific Antigen; C010792:testosterone undecanoate